Show document

A+ | A- | | SLO | ENG

Title: Prve slovenske klinične smernice za zdravljenje zmerne do hude luskavice s plaki pri odraslih bolnikih Authors: ID Šuler Baglama, Špela (Author) ID Starbek Zorko, Mateja (Author) ID Koser-Kolar, Nataša (Author) ID Šmuc Berger, Katarina (Author) ID Jović, Alen (Author) ID Lunder, Tomaž (Author) Files: PDF - Presentation file, download (271,56 KB) MD5: 98BBF60AA96B8E58939A11B70A09DE8E   URL - Source URL, visit https://vestnik.szd.si/index.php/ZdravVest/article/view/3713   Language: Slovenian Typology: 1.04 - Professional Article Organization: UKC LJ - Ljubljana University Medical Centre Abstract: Izhodišče in cilji: V zadnjih letih je odobritev novejših bioloških zdravil za obvladovanje zmerne do hude luskavice v plakih omogočila doseči višje cilje zdravljenja. Po drugi strani pa so te terapije povezane z bistveno višjimi stroški, kar ustvarja vse večji pritisk plačnikov zdravstvenih storitev, da bi zmanjšali skupne izdatke, zato vplivajo na prakso predpisovanja zdravil. Za podporo zdravnikom pri spopadanju s temi izzivi so se oblikovale prve slovenske smernice za obvladovanje zmerne do hude luskavice v plakih pri odraslih bolnikih. Njihov namen je zagotoviti na dokazih temelječe smernice, ki dermatovenerologom omogočajo, da v vsakem trenutku predpišejo terapijo, za katero menijo, da je najprimernejša za posameznega bolnika. Metode: Smernice so bile razvite z uporabo strukturiranega pristopa Delphi, ki temelji na soglasju. Združenje slovenskih dermatovenerologov je sklicalo in uradno odobrilo delovno skupino 6 slovenskih dermatovenerologov. Po pregledu obstoječih nacionalnih in mednarodnih smernic je skupina pripravila začetne izjave o priporočilih, ki so bile ponovno revidirane in izglasovane, dokler ni bilo doseženo 100-odstotno soglasje. Zaključene izjave so nato prejeli člani Združenja slovenskih dermatovenerologov, ki predpisujejo biološka zdravila za luskavico. In ti so o njih glasovali. Rezultati in zaključek: Rezultat tega procesa je bil trden, soglasno sprejeti sklop na dokazih temelječih priporočil za slovenske dermatovenerologe, ki zajemajo izbiro sistemskih terapij, uvedbo ter zaporedje posameznih bioloških zdravil, opredelitev zmerne do hude bolezni, določanje ciljev zdravljenja in določanje neuspeha zdravljenja. Keywords: klinične smernice, luskavica, biološka zdravila, sistemska terapija, zdravljenje Publication status: Published Publication version: Version of Record Year of publishing: 2026 Number of pages: str. D21-D30 Numbering: Vol. 95, no. 5/6 PID: 20.500.12556/DiRROS-31288  UDC: 615.5 ISSN on article: 1581-0224 DOI: 10.6016/ZdravVestn.3713  COBISS.SI-ID: 283707139  Note: Nasl. z nasl. zaslona; Opis vira z dne 6. 7. 2026; Publication date in DiRROS: 24.07.2026 Views: 85 Downloads: 55 Metadata:    Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:	Zdravniški vestnik : glasilo Slovenskega zdravniškega društva
Shortened title:	Zdr. vestn.
Publisher:	Slovensko zdravniško društvo
ISSN:	1581-0224
COBISS.SI-ID:	124545792

Licences

License:	CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:	http://creativecommons.org/licenses/by-nc/4.0/
Description:	A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Secondary language

Language:	English
Title:	First Slovenian clinical guidelines for the management of moderate-to-severe plaque psoriasis in adult patients
Abstract:	Background: In recent years, the approval of newer biological therapies for the management of moderate-to-severe plaque psoriasis has enabled the achievement of higher treatment goals. On the other hand, these therapies are associated with substantially higher costs, creating increasing pressure from healthcare payers to reduce overall expenditure and influencing prescribing practices. To support clinicians in navigating these challenges, the first Slovenian guidelines for the management of moderate-to-severe plaque psoriasis in adult patients have been developed. Their purpose is to provide evidence-based guidance that empowers dermatovenerologists to prescribe, at any given time, the therapy they consider most appropriate for the individual patient. Methods: The guidelines were developed using a structured, consensus-based Delphi approach. A working group of six Slovenian dermatovenereology specialists was convened and formally approved by the Association of Slovenian Dermatovenereologists. Following a review of existing national and international guidelines, the group drafted initial recommendation statements, which were iteratively revised and voted on until 100% consensus was reached. The finalized statements were subsequently distributed for voting to members of the Association of Slovenian Dermatovenereologists prescribing biological therapies for psoriasis. Results and conclusion: This process resulted in a robust, consensus-driven set of recommendations for Slovenian dermatovenerologists, providing evidence-based guidance on selecting systemic therapies, initiating and sequencing biological drugs, defining moderate-to-severe disease, establishing treatment goals, and determining treatment failure.
Keywords:	clinical guidelines, psoriasis, biologic drugs, systemic therapy, treatment

Back